-
2022-502043-35-00
5
Advanced Biliary Tract Cancers
-
2024-514355-16-01
5
Acute Respiratory Distress Syndrome (ARDS)
-
2024-517796-21-00
5
Prevention of recurrence after a first episode of Venous Thromboemboli
-
2024-518617-25-00
4
newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
-
2025-521836-12-00
4
deep vein thrombosis
-
2025-523555-66-00
5
Myelofibrosis
-
2025-524308-31-00
4
Acute myeloid leukemia
-
2025-521327-67-00
4
2026-04-13
Metastatic Castration-Resistant Prostate Cancer
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-514517-35-00
5
2025-02-27
Acute myeloid leukemia
-
2024-516874-31-00
5
2024-12-10
Patients with a low-grade serous epithelial carcinoma of the ovary (LG
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-512091-35-01
5
2025-06-17
Peripheral arterial disease
-
2023-504865-21-00
5
2024-04-15
Essential Thrombocythemia patients who have an inadequate response to
-
2022-502775-29-01
5
2023-12-14
Early stage Follicular Lymphoma
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2024-510690-16-00
5
2022-01-31
Relapsed/refractory follicular lymphoma
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2024-516316-13-00
4
2025-01-21
Merkel cell carcinoma without metastases in other organs and surgicall
-
2022-502043-35-01
5
2024-04-24
Advanced Biliary Tract Cancers
-
2022-501343-33-00
5
2023-10-18
Biochemically recurrent prostate cancer
-
2023-507187-39-00
5
2023-03-23
High-Risk Non-muscle-invasive Bladder Cancer
-
2023-510241-16-00
4
2021-12-03
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms